Although further studies are necessary, CGM data could be a valuable tool for detecting inadequate beta-pancreatic secretion and could serve to identify individuals who may benefit from treatment with DPP-4 inhibitors in the early stages of CFRD. The gene discussed is DPP4; the disease is cystic fibrosis-related diabetes.